Morgan Stanley
BRTX icon

Morgan Stanley’s BioRestorative Therapies BRTX Stock Holding History

Morgan Stanley’s Portfolio BRTX Stock Details BRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-35,000
Closed -$58.3K – 8187
2025
Q2 		$58.3K Sell
35,000
-3,000
-8% -$5.21K ﹤0.01% 6306
2025
Q1 		$67.6K Buy
38,000
+10,500
+38% +$20.1K ﹤0.01% 6171
2024
Q4 		$39.3K Buy
27,500
+10,000
+57% +$15.5K ﹤0.01% 6364
2024
Q3 		$30.4K Buy
17,500
+2,500
+17% +$4.12K ﹤0.01% 6364
2024
Q2 		$30.4K Buy
15,000
+5,000
+50% +$7.2K ﹤0.01% 6330
2024
Q1 		$13.8K Buy
+10,000
New +$15.4K ﹤0.01% 6584
2022
Q2 		– Sell
-25
Closed – – 7814
2022
Q1 		$0 Buy
+25
New +$108 ﹤0.01% 7969

Other funds holding BRTX

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.2B AUM 26.51% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Morgan Stanley's BRTX Position: Q3 2025 in Review

Morgan Stanley sold out of BioRestorative Therapies (BRTX) in Q3 2025, closing a stake of 35,000 shares — an estimated $58.3K sold.

Morgan Stanley first reported a position in BRTX in Q1 2022 and held it in 7 quarters. The position peaked at $67.6K in Q1 2025. 14 funds tracked by Wall St. Rank hold BRTX as of Q3 2025.

  • Morgan Stanley reported no remaining BioRestorative Therapies position as of Q3 2025 after selling out during the quarter.
  • Morgan Stanley sold 35,000 BioRestorative Therapies shares in Q3 2025, an estimated $58.3K.
  • Morgan Stanley first reported a position in BioRestorative Therapies in Q1 2022 and held it in 7 quarters.
  • Morgan Stanley's BioRestorative Therapies position peaked at $67.6K in Q1 2025.
  • 14 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q3 2025.

Based on Morgan Stanley's 13F filing for Q3 2025, filed 14 Nov 2025.